Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas N O'Connor

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Cancer Heterogeneity and Plasticity|October 17, 2025
Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment ResponseErik S Knudsen, Thomas N O'Connor, Agnieszka K Witkiewicz
Cancers|May 11, 2024
Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based TherapyThomas N O'Connor, Emily Schultz, Jianxin Wang, et al.
Oncogene|February 26, 2025
Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancerAgnieszka K Witkiewicz, Jianxin Wang, Emily Schultz, et al.
JCO Precision Oncology|January 23, 2026
Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 InhibitorsThomas N O'Connor, Emily Schultz, Sheheryar Kabraji, et al.
Oncogenesis|April 24, 2026
Cyclin E modulates vulnerability to CDC7 kinase inhibitionAdam P Dommer, Robert Kyne, Jianxin Wang, et al.
Molecular Cancer Therapeutics|August 16, 2024
Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease ModelsJin Wu, Jianxin Wang, Thomas N O'Connor, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|November 16, 2023
Cortical microglia dynamics are conserved during voluntary wheel runningAlexandra O Strohm, Thomas N O'Connor, Sadie Oldfield, et al.
NPJ Breast Cancer|December 1, 2025
Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancerYin Wan, Jianxin Wang, Thomas N O'Connor, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 28, 2024
Compound heterozygous RYR1-RM mouse model reveals disease pathomechanisms and muscle adaptations to promote postnatal survivalChen Liang, Sundeep Malik, Miao He, et al.
Cancer Research|February 13, 2025
Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222Adam P Dommer, Vishnu Kumarasamy, Jianxin Wang, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Cancer Heterogeneity and Plasticity|October 17, 2025
Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment ResponseErik S Knudsen, Thomas N O'Connor, Agnieszka K Witkiewicz
Cancers|May 11, 2024
Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based TherapyThomas N O'Connor, Emily Schultz, Jianxin Wang, et al.
Oncogene|February 26, 2025
Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancerAgnieszka K Witkiewicz, Jianxin Wang, Emily Schultz, et al.
JCO Precision Oncology|January 23, 2026
Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 InhibitorsThomas N O'Connor, Emily Schultz, Sheheryar Kabraji, et al.
Oncogenesis|April 24, 2026
Cyclin E modulates vulnerability to CDC7 kinase inhibitionAdam P Dommer, Robert Kyne, Jianxin Wang, et al.
Molecular Cancer Therapeutics|August 16, 2024
Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease ModelsJin Wu, Jianxin Wang, Thomas N O'Connor, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|November 16, 2023
Cortical microglia dynamics are conserved during voluntary wheel runningAlexandra O Strohm, Thomas N O'Connor, Sadie Oldfield, et al.
NPJ Breast Cancer|December 1, 2025
Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancerYin Wan, Jianxin Wang, Thomas N O'Connor, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 28, 2024
Compound heterozygous RYR1-RM mouse model reveals disease pathomechanisms and muscle adaptations to promote postnatal survivalChen Liang, Sundeep Malik, Miao He, et al.
Cancer Research|February 13, 2025
Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222Adam P Dommer, Vishnu Kumarasamy, Jianxin Wang, et al.
Pageof 2